RT Journal Article
T1 Rifabutin-Loaded Nanostructured Lipid Carriers as a Tool in Oral Anti-Mycobacterial Treatment of Crohn’s Disease
A1 Rouco Taboada, Helena
A1 Díaz Rodríguez, Patricia
A1 Gaspar, Diana P.
A1 Gonçalves, Lídia
A1 Cuerva Vidales, Miguel
A1 Remuñán López, Carmen
A1 Almeida, António J.
A1 Landín Pérez, Mariana
K1 Rifabutin
K1 Nanostructured lipid carriers
K1 Cell uptake
K1 Caco-2 cells
K1 Oral administration
K1 Crohn’s disease
AB Oral anti-mycobacterial treatment of Crohn’s disease (CD) is limited by the low aqueous solubility of drugs, along with the altered gut conditions of patients, making uncommon their clinical use. Hence, the aim of the present work is focused on the in vitro evaluation of rifabutin (RFB)-loaded Nanostructured lipid carriers (NLC), in order to solve limitations associated to this therapeutic approach. RFB-loaded NLC were prepared by hot homogenization and characterized in terms of size, polydispersity, surface charge, morphology, thermal stability, and drug payload and release. Permeability across Caco-2 cell monolayers and cytotoxicity and uptake in human macrophages was also determined. NLC obtained were nano-sized, monodisperse, negatively charged, and spheroidal-shaped, showing a suitable drug payload and thermal stability. Furthermore, the permeability profile, macrophage uptake and selective intracellular release of RFB-loaded NLC, guarantee an effective drug dose administration to cells. Outcomes suggest that rifabutin-loaded NLC constitute a promising strategy to improve oral anti-mycobacterial therapy in Crohn’s disease
PB MDPI
YR 2020
FD 2020
LK http://hdl.handle.net/10347/24061
UL http://hdl.handle.net/10347/24061
LA eng
NO Rouco, H.; Diaz-Rodriguez, P.; Gaspar, D.P.; Gonçalves, L.M.D.; Cuerva, M.; Remuñán-López, C.; Almeida, A.J.; Landin, M. Rifabutin-Loaded Nanostructured Lipid Carriers as a Tool in Oral Anti-Mycobacterial Treatment of Crohn’s Disease. Nanomaterials 2020, 10, 2138
NO This research was funded by V-A POCTEP Program (0245_IBEROS_1_E) of EU (FEDER), Xunta de Galicia (Competitive Reference Groups, ED431C 2016/008 and ED431C2017/09-FEDER), as well as by Fundação para a Ciência e Tecnologia, Portugal (under iMED.ULisboa project Pest-UID/DTP/04138/2019)
DS Minerva
RD 24 abr 2026